KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Non-Current Debt (2016 - 2022)

Pacific Biosciences Of California (PACB) has 10 years of Non-Current Debt data on record, last reported at $15.8 million in Q4 2019.

  • For Q4 2019, Non-Current Debt rose 7.78% year-over-year to $15.8 million; the TTM value through Dec 2019 reached $15.8 million, up 7.78%, while the annual FY2019 figure was $15.8 million, 7.78% up from the prior year.
  • Non-Current Debt reached $15.8 million in Q4 2019 per PACB's latest filing, up from $14.7 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $16.1 million in Q4 2016 and bottomed at $10.4 million in Q2 2017.
  • Average Non-Current Debt over 5 years is $14.2 million, with a median of $14.6 million recorded in 2015.
  • Peak YoY movement for Non-Current Debt: plummeted 33.8% in 2017, then skyrocketed 37.57% in 2018.
  • A 5-year view of Non-Current Debt shows it stood at $14.9 million in 2015, then grew by 7.75% to $16.1 million in 2016, then dropped by 15.34% to $13.6 million in 2017, then rose by 7.51% to $14.7 million in 2018, then grew by 7.78% to $15.8 million in 2019.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $15.8 million in Q4 2019, $14.7 million in Q4 2018, and $14.4 million in Q3 2018.